Bevacizumab News and Research

RSS

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.

21 Sep 2023

The role of diet in the management of retinal vein occlusion

Researchers investigate the potential impact of dietary habits on retinal vein occlusion.

27 Jul 2023

The potential prognostic role of AhRR and PPP1R3C expression in serous ovarian cancer

Study evaluated genes with copy number alterations to identify biomarkers for ovarian cancer prognosis.

18 Jul 2023

Mays Cancer Center conducts clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma

The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM).

24 May 2023

Study finds socio-economic inequalities in access to novel therapies for many NSCLC patients

Novel anti-cancer therapies were not accessible to more than half of the patients in England who were diagnosed with non-small cell lung cancer, according to a new study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

19 May 2023

Correcting abnormalities in solid tumor's blood vessels can improve efficacy of CAR-T cell therapy

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited efficacy against glioblastoma-;the deadliest type of primary brain cancer-;and other solid tumors.

14 Mar 2023

Pembrolizumab offers major added survival benefit for patients with advanced cervical cancer

Pembrolizumab has recently been approved in combination with chemotherapy for the treatment of women with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1. Chemotherapy with or without bevacizumab is possible.

25 Jan 2023

Plasma GH is a biomarker candidate for predicting outcomes in advanced HCC patients treated with Atezo/Bev

A new research paper was published in Oncotarget's Volume 13 on December 6, 2022, entitled, "Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients."

22 Dec 2022

Study compares the performance of two most popular AMD drugs

A pilot, "look-back" study of information about 106 patients with "wet" age-related macular degeneration (AMD) treated at the Wilmer Eye Institute at Johns Hopkins Medicine has revealed that nearly half of patients treated with aflibercept could safely stop eye injection therapy after one year without further vision loss.

30 Nov 2022

Researchers highlight the importance of localizing BRCA gene mutations for better ovarian cancer treatment

Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer.

28 Nov 2022

Combination of three existing drugs extends survival in mouse models of lethal brain cancer

A Ludwig Cancer Research study has identified a combination of three existing drugs that significantly extends survival in mouse models of the lethal brain cancer glioblastoma multiforme (GBM).

20 Sep 2022

A stepped regimen of anti-VEFG drugs leads to good vision outcomes in diabetic macular edema

Clinical trial results from the DRCR Retina Network suggest that a specific step strategy, in which patients with diabetic macular edema start with a less expensive medicine and switch to a more expensive medicine if vision does not improve sufficiently, gives results similar to starting off with the higher-priced drug.

14 Jul 2022

Researchers identify substantial lack of racial and ethnic data in studies of rare genetic disorder

In a review of published research papers, investigators from the Johns Hopkins Medicine Hereditary Hemorrhagic Telangiectasia Center have identified a substantial lack of racial and ethnic data that may be negatively impacting the treatment and diagnosis of this rare disorder in diverse patients.

11 Jul 2022

Combination of three technologies makes potential treatment effective against aggressive brain tumor

A drug carrier able to reach the brain, bind to an aggressive type of tumor called glioblastoma multiforme, and release a chemotherapeutic agent has been tested for the first time by Brazilian researchers.

15 Jun 2022

Black, Hispanic patients with advanced liver cancer have lower chance of receiving immunotherapy

Racial and ethnic minorities diagnosed with advanced liver cancer have a lower chance of receiving immunotherapy, the most effective treatment for patients with the disease, according to a new study led by Cedars-Sinai Cancer investigators.

8 Jun 2022

Treatment for retinal vein occlusion yields long-lasting vision gains, study shows

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years.

21 Apr 2022

Death rates from ovarian cancer are predicted to fall by 2022 in EU countries

Death rates from ovarian cancer are predicted to fall by 17% in the UK and by 7% in EU countries in 2022 compared to 2017, according to new research published in the leading cancer journal Annals of Oncology today (Wednesday).

27 Jan 2022

Independent drug action responsible for greater clinical efficacy of combination cancer therapies

Independent drug action, not synergy nor additivity, accounted for the clinical efficacy of nearly all examined combination therapies involving immune checkpoint inhibitors in clinical trials, according to results from a retrospective analysis.

19 Jan 2022

Folic acid-like drug reprograms DNA methylome of aggressive brain tumors

A folic acid-like drug, L-methylfolate, when administered alongside the standard therapy for patients with recurrent glioblastoma, changed aDNA process within their brain tumors, according to results from a phase 1 clinical trial.

5 Jan 2022

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer, according to results presented at the 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held online October 6-8, 2021.

6 Oct 2021